Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Myovant's Relugolix May Be Competitive With AbbVie Drug In Uterine Fibroids

Executive Summary

Relugolix meets primary and six key secondary endpoints in first Phase III UF study. Magnitude of benefit for primary endpoint does not equal AbbVie’s elagolix, but Myovant thinks it will offer safety, tolerability and convenience advantages.

Advertisement

Related Content

Allergan's Ulipristal, Dogged By Liver Concerns, Gets An FDA Rejection
AbbVie Prices Oral Endometriosis Drug Orilissa In Value Range, Focusing On Access
Roivant Cuts Jobs, Reallocates Staff As It Prepares To Put New Stars In The Spotlight
AbbVie's Got A Competitive Edge With Elagolix For Women With Uterine Fibroids
Takeda Continues To Shed Pipeline Assets In Roivant Deal

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC125219

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel